ClinicalTrials.gg
RecruitingNCT05499741Updated Mar 17, 2025

Forehead Temperature-Regulating Therapy for Insomnia in Adults With Tourette's Disorder

An interventional study of Forehead Temperature-Regulating Therapy in Tourette's Disorder and Insomnia, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.

Planned enrollment
62nd of 105
25 · median 33
Started
2023
with 7 others
No phase
48 of 139
10 open now
Primary completion
2026-01
later than 3 of 23 live
Registered
121st of 139
by date

Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 62nd largest by planned enrollment of the 105 interventional ones that give a count, is one of 8 that started in 2023, is one of 48 with no phase, reaches primary completion later than 3 of the 23 other live ones, and was the 121st registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Tourette Syndrome with a site in United States, or all of them as a file.
02

Study summary

The primary aim of the present research project is to investigate the preliminary effects of four weeks of forehead temperature-regulating therapy on insomnia in adults with Tourette's disorder and co-occurring insomnia disorder. This project will also examine the effects of the device on depression, anxiety, and daytime sleepiness, and explore its effects on tic severity.

Read the detailed description

Tourette's disorder is a neurological condition marked by multiple motor tics and one or more vocal tics present for longer than one year, and neural dysfunction within the frontal region of the brain. Sleep disturbance, particularly insomnia, is common in Tourette's disorder. Existing treatments (medication, behavior therapy) for Tourette's disorder do not benefit everyone. The sleep-wake cycle, which may overlap with Tourette's disorder with respect to underlying brain-based deficits, provides a key target for tailored intervention. Forehead temperature-regulating therapy, designed to treat insomnia through targeting underlying brain-based functioning, provides one such intervention. Therefore, the aim of the present investigation is to examine the preliminary effects of forehead temperature-regulating therapy on 1) insomnia, 2) depression, anxiety and daytime sleepiness, and 3) tic severity in adults with Tourette's disorder and co-occurring insomnia disorder.

Participation involves an initial assessment, during which an evaluator will screen for psychiatric and sleep disorder diagnosis, tic severity, and cognitive functioning. Participants will rate sleep apnea risk, insomnia severity, depression, anxiety, and daytime sleepiness. Participants will then monitor sleep for seven consecutive nights by wearing a wrist actigraph (sleep watch) and completing a sleep diary. Participants will then complete a pre-treatment evaluation, during which an evaluator will reassess tic severity, and participants will rate depression, anxiety, and daytime sleepiness. After the pre-treatment evaluation, participants will use a forehead temperature-regulating therapy device nightly for four weeks. Participants will use the actigraph and sleep diary to monitor sleep continuously for the remainder of the study. Following the intervention, participants will complete a post-treatment assessment involving clinician-rated tic severity interview, and re-rating of depression, anxiety, and daytime sleepiness measures. Findings will help researchers determine the degree to which non-medication treatments are helpful for insomnia in people with Tourette's disorder.

03

Conditions studied

  • Tourette's Disorder
  • Insomnia

Keywords

  • tics
  • insomnia
  • sleep
  • temperature
  • device
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of Tourette's disorder
  • DSM-5 diagnosis of Insomnia disorder
  • Yale Global Tic Severity Scale Score ≥ 14 for Tourette's disorder or ≥ 10 for persistent motor tic disorder or persistent vocal tic disorder
  • Insomnia Severity Index score > 14
  • Sleep efficiency ≤ 85 per cent on 50 percent or greater nights over monitoring week, per Consensus Sleep Diary
  • Age of 18 to 50 years
  • English fluency

Exclusion criteria

Exclusion Criteria:

  • Current or lifetime diagnosis of bipolar disorder, psychosis, or pervasive developmental disorder
  • Suicidality, severe depression or anxiety, or alcohol or substance dependence present within the past 6 months
  • Moderate to severe sleep apnea risk per score of ≥ 3 on the Stop-Bang Questionnaire
  • current diagnosis of Narcolepsy
  • Wechsler Abbreviated Scale for Intelligence-Second Edition IQ score \< 80
  • Changes in prescribed or over-the-counter medications for sleep within prior month and planned during the study
  • Changes in tic or other psychotropic medication within prior month and planned during study
  • Caffeine use > 3 cups per day
  • Behavior therapy for tics or sleep within prior 3 months
  • Travel across > 2 time zones in prior month
  • Shift work, or irregular sleep schedule (i.e., nightly variation of > 3 hours in bedtime or wake time, or time in bed duration \< 5.5 or > 10 hours per night)
  • Raynaud's disease or severe cold sensitivity
  • Other major medical or neurological condition
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Forehead Temperature-Regulating Therapy

    Forehead Temperature-Regulating Therapy

    Device: Forehead Temperature-Regulating Therapy

Interventions

  • DeviceForehead Temperature-Regulating Therapy

    A forehead thermal therapy device will be used nightly for the duration of each sleep period for four weeks. This device includes a bedside unit and a pump to transport thermal fluid to a bladder, affixed to the forehead with a headband. The bladder circulates fluid over the forehead at adjustable temperatures ranging from 57-61 °F.

    Also known as: Ebb CoolDrift Versa

06

What researchers measure

Primary outcomes

  1. Actigraphy - Sleep Onset Latency

    Sleep onset latency will be measured via a wrist actigraph and is defined as duration in minutes between time in bed and sleep onset. An actigraph (Actiwatch Spectrum PRO, Philips Respironics, Amsterdam, Netherlands), worn on the non-dominant wrist, will record daily and nightly movement/activity. Actigraphs will be set to record movements in 30-second epochs. Actigraphy data will be converted into sleep-wake scores guided by sleep diary bed times and rise times.

    Time frame: 5 weeks

  2. Actigraphy - Wake After Sleep Onset

    Wake after sleep onset will be measured via a wrist actigraph and is defined as the total number of minutes spent awake following sleep onset. An actigraph (Actiwatch Spectrum PRO, Philips Respironics, Amsterdam, Netherlands), worn on the non-dominant wrist, will record daily and nightly movement/activity. Actigraphs will be set to record movements in 30-second epochs. Actigraphy data will be converted into sleep-wake scores guided by sleep diary bed times and rise times.

    Time frame: 5 weeks

Secondary outcomes

  1. Depression Anxiety Stress Scale (DASS)-21 - Depression

    The DASS-21 (Lovibond \& Lovibond, 1995) is a 21-item self-report measure of depression, anxiety, and stress symptoms in the past week. Items are rated according to a 0- to- 3 scale and summed to yield independent depression, anxiety, and stress scores. Subscale scores are normed by multiplying them by two. Higher scores indicate increased negative affect.

    Time frame: 5 weeks

  2. Depression Anxiety Stress Scale (DASS)-21 - Anxiety

    The DASS-21 (Lovibond \& Lovibond, 1995) is a 21-item self-report measure of depression, anxiety, and stress symptoms in the past week. Items are rated according to a 0- to- 3 scale and summed to yield independent depression, anxiety, and stress scores. Subscale scores are normed by multiplying them by two. Higher scores indicate increased negative affect.

    Time frame: 5 weeks

  3. Epworth Sleepiness Scale (ESS)

    The ESS (Johns, 1991) is an 8-item self-reported measure of daytime sleepiness assessing potential for dozing or falling asleep across 8 situations. Items are rated on a 0- to- 3-scale and summed to yield a total score ranging from 0 to 24. Higher scores indicated increased daytime sleepiness.

    Time frame: 5 weeks

Other outcomes

  1. Yale Global Tic Severity Scale (YGTSS) - Total Tic Severity Score

    The YGTSS (Leckman et al., 1989) is a clinician-rated measure of tic symptom severity and tic-related impairment. Tic severity is assessed across number, frequency, intensity, complexity, and interference. Ratings are summed to produce separate scores for motor tics (0-25) and vocal tics (0-25), which are then summed to produce a total tic severity score (0-50).

    Time frame: 5 weeks

07

Study locations

1 of 1 sites recruiting
  • Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles
    Los Angeles, California 90095, United States
    Recruiting
    • Maya Tooker, BS · ContactMTooker@mednet.ucla.edu · (310) 825-2701
    • Emily J Ricketts, PhD · Principal investigator
08

References and documents

Publications

  • Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry. 1989 Jul;28(4):566-73. doi: 10.1097/00004583-198907000-00015. PubMed 2768151 ↗
  • Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther. 1995 Mar;33(3):335-43. doi: 10.1016/0005-7967(94)00075-u. PubMed 7726811 ↗
  • Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991 Dec;14(6):540-5. doi: 10.1093/sleep/14.6.540. PubMed 1798888 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jan 2026, 33 months after the start.

Of 65 non-industry interventional studies with no phase under Tourette Syndrome, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 50. This study's planned 33 months is close to that.

Counting every sponsor, half of 65 studies reached it within 33 months; a quarter within 22 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2022
First posted
Aug 12, 2022
StartActual
Apr 27, 2023
Primary completionEst.
Jan 2026
CompletionEst.
Jan 2026
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05499741
Collaborators
Brain & Behavior Research Foundation
Responsible party
Emily J. Ricketts, PhD (Assistant Clinical Professor, University of California, Los Angeles) — Principal investigator
First posted
Aug 12, 2022
Start date
Apr 27, 2023
Primary completion
Jan 2026 (estimated)
Completion
Jan 2026 (estimated)
Last update
Mar 17, 2025

Study contacts

Maya Tooker, BS
Contact
MTooker@mednet.ucla.edu
(310) 825-2701
Emily J Ricketts, PhD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion